Lubiprostone

This article needs additional citations for verification. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  –  ·  ·  · scholar · JSTOR (April 2014) (Learn how and when to remove this template message)

Lubiprostone

Clinical data
Trade names	Amitiza
Other names	Amitiza RU-0211 SPI-0211
AHFS/Drugs.com	Monograph
MedlinePlus	a607034
License data	US FDA: Lubiprostone
Routes of administration	Oral
ATC code	A06AX03 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	Negligible
Protein binding	94%
Metabolism	Extensive, CYP not involved
Elimination half-life	Unknown (lubiprostone) 0.9–1.4 hours (main metabolite)
Excretion	Renal (60%) and fecal (30%)
Identifiers
IUPAC name 7-[(1R,3R,6R,7R)-3-(1,1-Difluoropentyl)-3-hydroxy-8-oxo-2-oxabicyclo[4.3.0]non-7-yl]heptanoic acid
CAS Number	136790-76-6 Y
PubChem CID	157920
IUPHAR/BPS	4242
DrugBank	DB01046 Y
ChemSpider	138948 Y
UNII	7662KG2R6K
KEGG	D04790 Y
ChEMBL	ChEMBL1201134 N
CompTox Dashboard (EPA)	DTXSID5048639
ECHA InfoCard	100.107.168
Chemical and physical data
Formula	C20H32F2O5
Molar mass	390.468 g·mol−1
3D model (JSmol)	Interactive image
SMILES FC(F)(CCCC)[C@]2(O)O[C@@H]1CC(=O)[C@@H]([C@H]1CC2)CCCCCCC(=O)O
InChI InChI=1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15-,17-,20-/m1/s1 Y Key:WGFOBBZOWHGYQH-MXHNKVEKSA-N Y
NY (what is this?)

Lubiprostone (rINN, marketed under the trade name Amitiza among others) is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company.

The drug was developed by Sucampo Pharmaceuticals and approved by the Food and Drug Administration (FDA) in 2006.^[1][2][3] It was recommended for use in the UK by the National Institute for Health and Care Excellence (NICE) in July 2014.^[4] Health Canada approved the drug in 2015.^[5]

The cost to the NHS was £29.68 per 24 mcg 28-cap pack as of April 2017.

Lubiprostone received approval from the Food and Drug Administration in 2008 to treat irritable bowel syndrome with constipation (IBS-C),^[6] and in 2013 for the treatment of OIC in adults with chronic noncancer pain.^[3] It is available through prescription only.^[7]

The drug is available in the United States, Japan, Switzerland, India, Bangladesh, United Kingdom, and Canada.

In Bangladesh and India, lubiprostone is marketed under the trade name Lubigut by , Lubilax by Beacon Pharmaceuticals, and under the trade name Lubowel by Sun Pharmaceutical.

Medical uses[]

Lubiprostone is a laxative used for the treatment of constipation, specifically:^[8]

• Chronic idiopathic constipation (difficult or infrequent passage of stools that lasts for 3 months or longer and is not caused by diet, disease, or drugs).^{[8][2][7][9][10][11][12]}

• Constipation caused by certain opioid (narcotic) pain medications in people with chronic (on-going), noncancer pain,^[8] or in patients with long-lasting pain caused by a previous cancer or its treatment who do not need weekly increases in opioid dosage.^{[3][7][10][11]}
  • The effectiveness of lubiprostone has not been established in patients who are taking a diphenylheptane opioid (e.g., methadone).^[2][10]

• Irritable bowel syndrome with constipation (IBS-C; a condition that causes stomach pain or cramps, bloating, and infrequent or difficult passage of stools) in women who are at least 18 years of age.^{[8][2][6][7][9][10][11][12]}

Lubiprostone has not been studied in children.^[7][10] There is current research under way to determine the safety and efficacy in postoperative bowel dysfunction.

It comes in a liquid filled capsule and is available only with a doctor's prescription.^[7] If one misses a dose it should be taken as soon as possible unless it is almost time for the next dose, in which case it should be skipped and the user should return to their regular dosing schedule.^[7]

Adverse effects[]

In clinical trials, the most common adverse event was nausea (31%) . Other adverse events (≥5% of patients) included diarrhea (13%), headache (13%), abdominal distension (5%), abdominal pain (5%), flatulence (6%), sinusitis (5%), vomiting (5%), and fecal incontinence (1%).

The FDA lists the following:^[2]

For subjects with Chronic Idiopathic Constipation taking Amitiza:

• Nausea ~ 29% (4% were severe, and 9% of patients discontinued treatment due to nausea. The rate of nausea was lower among male (8%) and elderly (19%) patients. No patients in the clinical studies were hospitalized due to nausea.)
• Diarrhea: ~12% (2% were severe, and 2% of patients discontinued treatment due to diarrhea)
• Several less common adverse reactions (<1%).

For Opioid-Induced Constipation:

• Nausea: ~ 11%; 1% severe nausea and 2% discontinued treatment due to nausea.
• Diarrhea: ~ 8%; 2% severe diarrhea and 1% of patients discontinued treatment due to diarrhea.
• Less common adverse reactions (<1%): fecal incontinence, blood potassium decreased.

For subjects with Irritable Bowel Syndrome with Constipation:

• Nausea: ~ 8%; 1% severe nausea and 1% discontinued treatment due to nausea.
• Diarrhea: ~ 7%; <1% of patients had severe diarrhea and <1% of patients discontinued treatment due to diarrhea.
• Less common adverse reactions: <1%^[2]

A 2018 pooled analysis from three phase III, randomized, double-blind, placebo-controlled studies on usage for Opioid-Induced Constipation, found that the numbers of patients reporting adverse effects were similar in both the lubiprostone and placebo treatment groups for all opioid classes (P ≥ 0.125); however, gastrointestinal adverse effects were reported more frequently by those receiving lubiprostone than 2 of the 3 opioid groups. The most commonly reported TEAEs in the lubiprostone treatment groups were nausea (13.4%–18.1%), diarrhea (1.2%–13.9%), and abdominal pain (4.7%–5.6%). In the population overall, the greatest likelihood of experiencing the first episode of any of these three TEAEs was greatest in the first week of treatment and decreased thereafter.^[3]

According to Medscape, the most common (>10%) were: Nausea , Diarrhea (7-12%), Headache (2-11%). Less common side effects (1-10%) included: Abdominal pain (4-8%), Abdominal distension (3-6%), Flatulence (4-6%), Vomiting (3%), Loose stools (3%), Edema (1-3%), Abdominal discomfort (1-3%), Dizziness (3%), Chest discomfort/pain (2%), Dyspnea (2%), Dyspepsia (2%), Fatigue (2%), Dry mouth (1%).^[11]

Contraindications[]

• Known or suspected mechanical GI obstruction.^[2][12][10]
• Known hypersensitivity to lubiprostone or any ingredient in the formulation.^[12]

There is no current data on use in people with liver or kidney complications. The effects on pregnancy have not been studied in humans but testing in guinea pigs resulted in fetal loss.

Amitiza is not approved for use in children. Lubiprostone is contraindicated in patients exhibiting chronic diarrhea, bowel obstruction, or diarrhea-predominant irritable bowel syndrome.

Mechanism of action[]

Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM).

Symptoms of constipation such as pain and bloating are usually improved within one week, and SBM may occur within one day.

Pharmacokinetics[]

Unlike many laxative products, lubiprostone does not show signs of drug tolerance, chemical dependency, or altered serum electrolyte concentration.^[13] There was no rebound effect following withdrawal of treatment, but a gradual return to pre-treatment bowel movement frequency should be expected.

Minimal distribution of the drug occurs beyond the immediate gastrointestinal tissues. Lubiprostone is rapidly metabolized by reduction/oxidation, mediated by carbonyl reductase. There is no metabolic involvement of the hepatic cytochrome P450 system. The measurable metabolite, M3, exists in very low levels in plasma and makes up less than 10% of the total administered dose.

Data indicate that metabolism occurs locally in the stomach and jejunum.

References[]

External links[]

• Official website